Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance

Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance

The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to placebo in lowering post-meal blood glucose levels in people with pre-diabetes who have high blood sugar levels after meals.

Inclusion Criteria:

• Blood glucose criteria must be met
• Body mass index (BMI) in the range 23-45

Exclusion Criteria:

• Diagnosis of diabetes
• Serious cardiovascular events within the past 6 months
• Use of insulin or any oral antidiabetic agent
• Other protocol-defined exclusion criteria may apply